Dr. Lauren Byers, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Baylor University

  Medical School, 2003

• Teaching an old dog new tricks: Drug repositioning in small cell lung cancer, 2013-12-17

• Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?, 2015-05-15

• Smoking, p53 Mutation, and Lung Cancer, 2014-02-04

• Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lung cancer., 2019-08-27

• Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies, 2017-09-01

• Small Cell Lung Cancer: Where Do We Go From Here?, 2014-10-21

• Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a target inLKB1Mutant Lung Cancer, 2013-05-28

• PARP1 as a potential therapeutic target in Merkel cell carcinoma, 2018-03-23

• Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas, 2018-04-03

• Development and Validation of a Prognostic Gene-Expression Signature for Lung Adenocarcinoma, 2012-09-07

• Assessing the clinical utility of cancer genomic and proteomic data across tumor types, 2014-06-22

• CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells, 2017-05-24

• Characterization of Human Cancer Cell Lines by Reverse-Phase Protein Arrays, 2017-02-13

• ZEB1 Induces LOXL2-Mediated Collagen Stabilization and Deposition in the Extracellular Matrix to Drive Lung Cancer Invasion and Metastasis, 2016-10-03

• Dual inhibition of MEK and AXL targets tumor cell heterogeneity and prevents resistant outgrowth mediated by the epithelial-to-mesenchymal transition in NSCLC, 2021-01-05

• Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy, 2019-05-24

• BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study, 2023-02-18

• Functional Characterization of CLPTM1L as a Lung Cancer Risk Candidate Gene in the 5p15.33 Locus, 2012-06-04

• Resolving the spatial and cellular architecture of lung adenocarcinoma by multi-region single-cell sequencing, 2021-05-10

• Evading the STING: LKB1 loss leads to STING silencing and immune escape in KRAS-mutant lung cancers, 2021-07-22

• Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia, 2020-09-13

• Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer, 2017-02-15

• The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers, 2015-03-23

• Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer, 2020-02-17

• Small Cell Lung Cancer: Can recent advances in biology and molecular biology be translated into improved outcomes?, 2016-01-30

• ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism, 2019-03-13

• Co-occurring genomic alterations define major subsets ofKRAS -mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities, 2015-06-11

• CDKN2A/p16 deletion in head and neck cancer cells is associated with Cdk2 activation, replication stress, and vulnerability to Chk1 inhibition, 2017-12-11

• STING pathway expression identifies non-small cell lung cancers with an immune-responsive phenotype, 2020-02-15

• Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC, 2022-11-22

• An epithelial-mesenchymal transition (EMT) gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance, 2012-10-22

• AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers, 2016-09-26

• A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma, 2014-09-05

• Using Reverse-Phase Protein Arrays (RPPAs) as Pharmacodynamic Assays for Functional Proteomics, Biomarker Discovery, and Drug Development in Cancer, 2016-06-15

• Progress in the Management of Limited-Stage Small Cell Lung Cancer, 2013-12-10

• Di fferential S ensitivity A nalysis for R esistant M alignancies (DISARM) identifies common candidate therapies across platinum-resistant cancers, 2018-09-26

• Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer, 2021-11-17

• AXL inhibition induces DNA damage and replication stress in non-small cell lung cancer cells and promotes sensitivity to ATR inhibitors, 2020-11-10

• HRAS Mutations and Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Head and Neck Squamous Cell Carcinoma Cells, 2014-03-20

• Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial, 2023-03-16

• Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer, 2017-07-11

• Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial, 2021-02-18

• High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer, 2019-12-16

• A pan-cancer proteomic perspective on The Cancer Genome Atlas, 2014-05-29

• Single-Cell Expression Landscape of SARS-CoV-2 ReceptorACE2and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients, 2021-03-12

• Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance inKRAS/p53mutant lung cancers, 2021-05-10

• Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma, 2022-05-11

• Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivatingBRAFmutations, 2015-11-23

• A Reversible Shift of Driver Dependence from EGFR to Notch1 in Non-Small Cell Lung Cancer as a Cause of Resistance to Tyrosine Kinase Inhibitors, 2021-04-22

• CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib, 2017-05-10

• Integrated Approaches for the Use of Large Datasets to Identify Rational Therapies for the Treatment of Lung Cancers, 2019-02-19

• Comparative genomics of high grade neuroendocrine carcinoma of the cervix, 2020-06-16

• Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities, 2021-01-21

• Targeting DNA damage response promotes anti-tumor immunity through STING-mediated T-cell activation in small cell lung cancer, 2019-02-18

• Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer, 2021-09-23

• Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer, 2015-11-23

• Integrative analysis identifies a novel AXL-PI3 kinase-PD-L1 signaling axis associated with radiation resistance in head and neck cancer, 2017-05-05

• Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression, 2014-10-28

• Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+T cell exhaustion, 2020-09-09

• Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma, 2016-02-05

• NOTCH1 Signaling in Head and Neck Squamous Cell Carcinoma, 2020-12-12

• Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer, 2016-04-07

• A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial to mesenchymal transition, 2015-09-29

• A Phase II Study of Talazoparib in Patients with Homologous Recombination Repair Deficient Squamous Cell Lung Cancer (Lung-MAP Sub-Study S1400G), 2021-01-10

• Beyond chemotherapy - emerging biomarkers and therapies as SCLC enters the immune checkpoint era, 2019-01-08

• Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced GermlineBRCA1/2Mutations and Selected Sporadic Cancers, 2017-02-27

• Association of Medicaid Insurance With Survival Among Patients With Small Cell Lung Cancer Association of Medicaid Insurance With Survival Among Patients With Small Cell Lung Cancer, 2020-04-22

• Prognostic Significance of Pretreatment Total Lymphocyte Count and Neutrophil-to-Lymphocyte Ratio in Extensive-Stage Small-Cell Lung Cancer, 2018-02-02

• The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response, 2020-12-16

• The MEK5-ERK5 kinase axis controls lipid metabolism in small cell lung cancer, 2020-01-22

• Sequencing of Mutational Hotspots in Cancer-Related Genes in Small Cell Neuroendocrine Cervical Cancer, 2016-04-15